Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

NCT06446570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
Head and Neck Neoplasms

Interventions

DRUG: Durvalumab,Tremelimumab

Sponsor

Seoul National University Hospital

Collaborators

[object Object]